Kyverna Shares Rise Premarket After Promising Trial of Neurological Product

Dow Jones

Apr 22

By Rob Curran

Kyverna Therapeutics' stock was higher before the market's open after a treatment for a rare neurological condition showed promise in a mid-stage clinical trial.

Shares of Kyverna were up 20% at $11.68 in premarket trading.

The Emeryville, Calif., biotechnology company said its mivocabtagene autoleucel, or KYV-101, product was tested on patients with stiff person syndrome in a phase II trial. After 16 weeks on the treatment, the majority of the 26 patients with the autoimmune condition regained function and one-third of them were able to walk at a typical adult speed.

"We see compelling evidence that a one-time therapy can reset the immune system, reverse the course of disease, and free patients from lifelong treatment burden," said Chief Executive Warren Biddle, in a statement.

Canadian singer Celine Dion suffers from stiff person syndrome and supports research into the neurological condition. The lead investigator for the trial, Dr. Amanda Piquet, is the Celine Dion Foundation endowed chair and the director of autoimmune neurology at the University of Colorado Anschutz School of Medicine.

Write to Rob Curran at rob.curan@dowjones.com

(END) Dow Jones Newswires

April 22, 2026 06:35 ET (10:35 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2629017990"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2629017990\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2629017990?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-22 18:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629017990","market":"other","top_or_hot":-1,"title":"Kyverna Shares Rise Premarket After Promising Trial of Neurological Product","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/KYTX\">Kyverna Therapeutics</a>' stock was higher before the market's open after a treatment for a rare neurological condition showed promise in a mid-stage clinical trial. \n</p>\n<p>\n  Shares of Kyverna were up 20% at $11.68 in premarket trading. \n</p>\n<p>\n  The Emeryville, Calif., biotechnology company said its mivocabtagene autoleucel, or KYV-101, product was tested on patients with stiff person syndrome in a phase II trial. After 16 weeks on the treatment, the majority of the 26 patients with the autoimmune condition regained function and one-third of them were able to walk at a typical adult speed. \n</p>\n<p>\n  \"We see compelling evidence that a one-time therapy can reset the immune system, reverse the course of disease, and free patients from lifelong treatment burden,\" said Chief Executive Warren Biddle, in a statement. \n</p>\n<p>\n  Canadian singer Celine Dion suffers from stiff person syndrome and supports research into the neurological condition. The lead investigator for the trial, Dr. Amanda Piquet, is the Celine Dion Foundation endowed chair and the director of autoimmune neurology at the University of Colorado Anschutz School of Medicine. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curan@dowjones.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 22, 2026 06:35 ET (10:35 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kyverna Shares Rise Premarket After Promising Trial of Neurological Product</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKyverna Shares Rise Premarket After Promising Trial of Neurological Product\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-22 18:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/KYTX\">Kyverna Therapeutics</a>' stock was higher before the market's open after a treatment for a rare neurological condition showed promise in a mid-stage clinical trial. \n</p>\n<p>\n  Shares of Kyverna were up 20% at $11.68 in premarket trading. \n</p>\n<p>\n  The Emeryville, Calif., biotechnology company said its mivocabtagene autoleucel, or KYV-101, product was tested on patients with stiff person syndrome in a phase II trial. After 16 weeks on the treatment, the majority of the 26 patients with the autoimmune condition regained function and one-third of them were able to walk at a typical adult speed. \n</p>\n<p>\n  \"We see compelling evidence that a one-time therapy can reset the immune system, reverse the course of disease, and free patients from lifelong treatment burden,\" said Chief Executive Warren Biddle, in a statement. \n</p>\n<p>\n  Canadian singer Celine Dion suffers from stiff person syndrome and supports research into the neurological condition. The lead investigator for the trial, Dr. Amanda Piquet, is the Celine Dion Foundation endowed chair and the director of autoimmune neurology at the University of Colorado Anschutz School of Medicine. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curan@dowjones.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 22, 2026 06:35 ET (10:35 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2629017990","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629017990","pubTimestamp":1776854100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Kyverna Therapeutics' stock was higher before the market's open after a treatment for a rare neurological condition showed promise in a mid-stage clinical trial.Shares of Kyverna were up 20% at $11.68 in premarket trading.The Emeryville, Calif., biotechnology company said its mivocabtagene autoleucel, or KYV-101, product was tested on patients with stiff person syndrome in a phase II trial. After 16 weeks on the treatment, the majority of the 26 patients with the autoimmune condition regained function and one-third of them were able to walk at a typical adult speed.\"We see compelling evidence that a one-time therapy can reset the immune system, reverse the course of disease, and free patients from lifelong treatment burden,\" said Chief Executive Warren Biddle, in a statement.Canadian singer Celine Dion suffers from stiff person syndrome and supports research into the neurological condition. The lead investigator for the trial, Dr. Amanda Piquet, is the Celine Dion Foundation endowed ch","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KYTX":"Kyverna Therapeutics"},"translate_title":"神经产品试验前景看好后，Kyverna股价盘前上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KYTX":0.9},"content_text":"By Rob Curran \n\n\n \n\n\nKyverna Therapeutics' stock was higher before the market's open after a treatment for a rare neurological condition showed promise in a mid-stage clinical trial. \n\n\n  Shares of Kyverna were up 20% at $11.68 in premarket trading. \n\n\n  The Emeryville, Calif., biotechnology company said its mivocabtagene autoleucel, or KYV-101, product was tested on patients with stiff person syndrome in a phase II trial. After 16 weeks on the treatment, the majority of the 26 patients with the autoimmune condition regained function and one-third of them were able to walk at a typical adult speed. \n\n\n  \"We see compelling evidence that a one-time therapy can reset the immune system, reverse the course of disease, and free patients from lifelong treatment burden,\" said Chief Executive Warren Biddle, in a statement. \n\n\n  Canadian singer Celine Dion suffers from stiff person syndrome and supports research into the neurological condition. The lead investigator for the trial, Dr. Amanda Piquet, is the Celine Dion Foundation endowed chair and the director of autoimmune neurology at the University of Colorado Anschutz School of Medicine. \n\n\n \n\n\n  Write to Rob Curran at rob.curan@dowjones.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 22, 2026 06:35 ET (10:35 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}